Global Vasomotor Menopausal Symptoms (VMS) Treatment Market Projected to Grow at 6.5% CAGR, Reaching $24.5 Billion by 2029

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Vasomotor Menopausal Symptoms (VMS) Treatment Industry Market Size Be by 2025?
The market dedicated to treating vasomotor menopausal symptoms (VMS) has seen robust expansion lately, projected to move from a valuation of $17.86 billion in 2024 up to $19.01 billion come 2025, exhibiting a compound annual growth rate (CAGR) calculated at 6.5%; this upswing during the past period is linked to factors such as the utilization of hormone replacement therapy (HRT), heightened awareness surrounding menopause, advances in pharmaceutical science, and consumer purchasing impetus.

What's the Long-Term Growth Forecast for the Vasomotor Menopausal Symptoms (VMS) Treatment Market Size Through 2029?
The market encompassing treatments for vasomotor menopausal symptoms anticipates robust expansion in the coming years, projected to reach a valuation of $24.5 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.5% throughout this period. This predicted upward trajectory is fueled by several key factors, including advancements in personalized medicine, the emergence of novel non-hormonal therapeutic options, increased utilization of nutritional and dietary management strategies, and the growing adoption of both telemedicine and broader digital health solutions. Over the forecast horizon, prominent developments gaining traction involve a greater focus on natural and alternative methods, a rise in the incorporation of botanical and herbal preparations, the strengthening of menopause support communities, and the expanding application of cognitive behavioral therapy (CBT).

View the full report here:
https://www.thebusinessresearchcompany.com/report/vasomotor-menopausal-symptoms-vms-treatment-global-market-report

What Are the Key Growth Drivers Fueling the Vasomotor Menopausal Symptoms (VMS) Treatment Market Expansion?
The expanding demographic of women experiencing menopause is forecast to be the key catalyst boosting the market for treating vasomotor menopausal symptoms moving ahead. Menopause represents an inherent physiological transition signifying the cessation of female fertility, generally occurring for women between forty-five and fifty-five, with the mean age centering near fifty-one. A major determinant fueling the expansion of the market dedicated to treating VMS is the growing cohort of menopausal women worldwide requiring interventions for symptoms such as hot flashes and vaginal dryness. To illustrate this trend, an assessment released in November 2022 by the Cuyuna Regional Medical Center, an entity located in the United States, projected that longevity gains would result in 1.1 billion women reaching menopause by the year 2025. Further detailing this trend, the menopausal population is projected to expand at a yearly rate of 1.6 percent through 2060, consequently establishing the larger menopause demographic as the primary force propelling the development of the market targeting vasomotor menopausal symptom treatments.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13051&type=smp

What Are the Key Trends Driving Vasomotor Menopausal Symptoms (VMS) Treatment Market Growth?
Leading enterprises within the market focused on managing vasomotor symptoms associated with menopause are actively creating offerings such as Veozah and securing regulatory clearances to introduce novel therapeutic avenues and address unsatisfied patient requirements. The authorization of new pharmaceutical agents for menopause introduces enhanced effectiveness and superior safety profiles when set against current therapeutic modalities. Specifically, in May of 2023, the US federal regulatory body, the Food and Drug Administration (FDA), granted approval to Astellas Pharma Inc., a corporation originating from Japan, for its medication Veozah (fezolinetant) administered as a 45 mg dose every twenty-four hours, intended for addressing menopausal vasomotor symptoms (VMS) spanning the mild to severe spectrum. This medication stands out as the inaugural nonhormonal neurokinin 3 (NK3) receptor antagonist to gain official sanction for managing VMS linked to the menopausal transition; functioning as a hormone-exempt choice, it hinders a specific neural circuit in the brain responsible for controlling these manifestations. Consequently, it presents a distinct therapeutic alternative for females enduring these symptoms, especially those unable to use or consciously choosing to avoid hormone replacement therapy, with Veozah's reception underscoring its promise as an innovative pharmaceutical intervention for controlling symptoms of menopause.

How Is the Vasomotor Menopausal Symptoms (VMS) Treatment Market Segmented?
The vasomotor menopausal symptoms (vms) treatmentmarket covered in this report is segmented -

1) By Drug Class: Antidepressants; Fluoxetine; Paroxetine; Sertraline; Hormone Therapy; Anticonvulsant; Phenytoin; Phenobarbital; Other Drug Classes
2) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
3) By End-User: Hospitals; Specialty Clinics; Homecare; Other End-Users

Subsegments:
1) By Antidepressants: SSRIs (Selective Serotonin Reuptake Inhibitors); SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors); TCAs (Tricyclic Antidepressants); MAOIs (Monoamine Oxidase Inhibitors); Atypical Antidepressants
2) By Fluoxetine: Depression; Obsessive-Compulsive Disorder (OCD); Panic Disorder; Generalized Anxiety Disorder (GAD); Post-Traumatic Stress Disorder (PTSD); Social Anxiety Disorder; Premenstrual Dysphoric Disorder (PMDD)
3) By Paroxetine: Depression; Obsessive-Compulsive Disorder (OCD); Panic Disorder; Generalized Anxiety Disorder (GAD); Post-Traumatic Stress Disorder (PTSD); Social Anxiety Disorder; Premenstrual Dysphoric Disorder (PMDD)
4) Sertraline: Depression; Obsessive-Compulsive Disorder (OCD); Panic Disorder; Post-Traumatic Stress Disorder (PTSD); Social Anxiety Disorder; Premenstrual Dysphoric Disorder (PMDD)
5) Hormone Therapy: Estrogen Replacement Therapy (ERT); Progestin Therapy; Combined Hormonal Therapy (CHT); Testosterone Replacement Therapy (TRT)
6) Anticonvulsant: Hydantoins; Barbiturates; Benzodiazepines; Valproates; Succinimides; Carboxylic Acid Derivatives
7) Phenytoin: Hydantoins
8) Phenobarbital: Barbiturates
9) Other Drug Classes: Antibiotics; Analgesics; Antidiabetics; Antihypertensives; Anticoagulants; Immunosuppressants; Antipsychotics; Antihistamines

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13051&type=smp

Which Companies Are Leading the Charge in Vasomotor Menopausal Symptoms (VMS) Treatment Market Innovation?
Major companies operating in the vasomotor menopausal symptoms (vms) treatment market are Pfizer Inc., Abbvie Inc., Novartis AG, Ausio Pharmaceuticals LLC, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Kyowa Kirin Co. Ltd., Dr. Reddy's Laboratories Ltd., Alembic Pharmaceuticals Limited Inc., Apotex Inc., Hikma Pharmaceutical PLC, Endo Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Mundipharma International Ltd., Lupin Limited, Glenmark Pharmaceuticals Ltd., Hisamitsu Pharmaceutical Co. Inc., Zhejiang Huahai Pharmaceutical Co. Ltd., Emcure Pharmaceuticals Limited, Wockhardt Pvt. Ltd., QuatRx Pharmaceuticals Company, Bionovo Inc., Mithra Pharmaceuticals SA, EndoCeutics Inc., Zydus Group, Edgemont Pharmaceuticals LLC, MenoGeniX Inc., Agile Therapeutics Inc.

Which Regions Are Leading the Global Vasomotor Menopausal Symptoms (VMS) Treatment Market in Revenue?
North America was the largest region in the vasomotor menopausal symptoms (VMS) treatment market in 2024. The regions covered in vasomotor menopausal symptoms (VMS) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13051

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.